RenovoRx, Inc.
RNXT
$2.00
-$0.21-9.32%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
9/2/2026
-
Globe Newswire
9/2/2026
-
MarketBeat
8/30/2026
-
The Cerbat Gem
8/28/2026
-
MarketBeat
8/28/2026
-
TipRanks: TheFly
8/25/2026
-
TipRanks: TheFly
8/25/2026
-
Globe Newswire
8/21/2026
-
Seeking Alpha - Healthcare
8/21/2026
-
TipRanks: TheFly
8/21/2026
-
Globe Newswire
8/21/2026
-
TipRanks
8/20/2026
-
Globe Newswire
8/18/2026
-
MarketBeat
8/17/2026
-
MarketBeat
8/17/2026
-
MarketBeat
8/15/2026
-
MarketBeat
8/14/2026
-
TipRanks
8/13/2026
-
MarketBeat
8/13/2026
-
Fool.com Headlines
8/12/2026
-
The Cerbat Gem
8/12/2026
-
Zacks Investment Research
8/12/2026
-
MarketBeat
8/12/2026
-
Globe Newswire
8/11/2026
-
Zacks Investment Research
8/11/2026
-
TipRanks: TheFly
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, August 13, 2026
Period Date
Tuesday, June 30, 2026
Next Filing
Week of Nov 9 and 13 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
650 284 4433
Address
2570 West El Camino Real
Suite 320
Mountain View, CA 94040
Suite 320
Mountain View, CA 94040
Country
Year Founded
Business Description
Sector
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead...
more